Filtered By:
Procedure: Transplants
Vaccination: Measles Vaccine
This page shows you your search results in order of date.
Order by Relevance | Date
Total 72 results found since Jan 2013.
Real-world challenges in eligibility for MMR vaccination two years after autologous and allogeneic HSCT
Vaccine. 2023 Aug 29:S0264-410X(23)00778-8. doi: 10.1016/j.vaccine.2023.06.075. Online ahead of print.ABSTRACTMeasles outbreaks have raised concerns of fatal infections in immunocompromised patients. Canadian guidelines advise administration of live vaccines, such as measles, mumps, and rubella (MMR), two yearsafter hematopoietic stem cell transplant (HSCT) yet studies have not assessed eligibility based on medication contraindications. We retrospectively reviewed the charts of 72 autologous (auto-HSCT) and 68 allogeneic (allo-HSCT) recipients at the Windsor Regional Cancer Center to determine MMR reactivity and eligibilit...
Source: Vaccine - August 31, 2023 Category: Allergy & Immunology Authors: Gopika Punchhi Rainbow Negus Hammad Saif Sharon Pritchard Olivia Owen Aman Sehmbi Caroline Hamm Source Type: research
Measles, mumps, and rubella revaccination in children after completion of chemotherapy and hematopoietic stem cell transplantation: a single-center prospective efficacy and safety analysis
CONCLUSIONS: MMR revaccination is immunogenic for the population. We suggest periodic monitoring of antibody titers, in addition to a booster vaccination, although the optimal timing of booster vaccination remains to be investigated further.PMID:37087716 | DOI:10.1007/s12519-023-00721-x
Source: World Journal of Pediatrics : WJP - April 23, 2023 Category: Pediatrics Authors: Min Wang Qing Yuan Peng-Fei Deng Yi Fei Hua Zhang Fen Zhou Wen-Juan Chen Qing Cao Jing Chen Yi-Jin Gao Source Type: research
Measles, mumps and rubella vaccine 12 months after hematopoietic stem cell transplantation
The objectives of this study were to evaluate when patients received MMR vaccine after an HSCT in our care service and if there were reports of any side effects. We retrospectively reviewed the records of HSCT recipients who received at least one MMR dose in our care service, a quaternary teaching hospital in Sao Paulo city, Brazil, from 2017 to 2021. We identified 82 patients: 75.6% (90.1% in the autologous group and 45.1% in the allogeneic group) were vaccinated before 23 months post-transplantation. None reported side effects following the vaccination. Our data support that the MMR vaccination is safe from 12 to 23 mont...
Source: Revista do Instituto de Medicina Tropical de Sao Paulo - March 22, 2023 Category: Tropical Medicine Authors: Bruno Azevedo Randi Eder Gatti Fernandes Hermes Ryoiti Higashino Marta Heloisa Lopes Vanderson Geraldo Rocha Silvia Figueiredo Costa Ana Marli Christovam Sartori Source Type: research
Analysis of Immunity against Measles, Mumps, Rubella, and Varicella Zoster in Adult Recipients of Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Experience
Acta Med Okayama. 2022 Jun;76(3):247-253. doi: 10.18926/AMO/63718.ABSTRACTVaccine-preventable disease (VPD) infections are more severe in immunocompromised hosts. Vaccination against measles, mumps, rubella, and varicella zoster (VZV) (MMRV) is therefore recommended for hematopoietic stem cell transplantation (HCT) recipients. However, studies on adult HCT recipients with VPD infections are limited. At our institution, we have systematically conducted serological MMRV tests as a part of check-up examinations during long-term follow-up (LTFU) after HCT since 2015. This retrospective study aimed to evaluate changes in the se...
Source: Acta Med Okayama - July 5, 2022 Category: Universities & Medical Training Authors: Shohei Yoshida Nobuharu Fujii Chihiro Kamoi Wataru Kitamura Hideaki Fujiwara Noboru Asada Hisakazu Nishimori Keiko Fujii Ken-Ichi Matsuoka Yoshinobu Maeda Source Type: research
